The House Energy and Commerce Committee passed by a vote of 54-0 the legislation carrying the FDA user fee agreements with several provisions added, including amendments intended to bolster drug competition and a seemingly duplicative pilot program for medical device surveillance. The hearing was not without controversy, however, as the drug reimportation debate devoured a large portion of the hearing. Read More
